ArticleCureus2025
Achieving a Good Response in Myxofibrosarcoma With Uncontrollable Bleeding Using an Enzyme-Targeting Radiosensitization Treatment: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxofibrosarcoma is one of the most prevalent histological types of primary malignant soft tissue tumors of the extremity. Radiation therapy is frequently employed as a post-operative treatment. In this case report, we present a 78-year-old male with a large tumor on his forearm. He refused surgical treatment. Over a period of seven years, recurrence and bleeding were repeatedly observed. Kochi oxydol radiation therapy for unresectable carcinomas (KORTUC) is a treatment modality that uses a hydrogen peroxide solution that adheres to the tumor surface (KORUTC I), while the solution is also injected into the tumor (KORTUC II). We treated the tumor with KORTUC I and II. A good response was observed. This case report highlights the effectiveness of KORTUC I and II. Reports on KORTUC for sarcomas are limited, underscoring the necessity for future examination of cases not indicated for surgical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.